您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > STX-0119
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
STX-0119
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
STX-0119图片
CAS NO:851095-32-4
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
STX-0119 是一种选择性的、具有口服活性的STAT3二聚抑制剂。STX-0119 抑制 STAT3 转录，IC50为 74 μM。
生物活性

STX-0119 is a selective, orally activeSTAT3dimerization inhibitor. STX-0119 inhibitsSTAT3transcription with anIC50of 74 μM[1].

IC50& Target[1]

STAT3

74 μM (IC50, STAT3 transcription)

体外研究
(In Vitro)

STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells[1].
STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins[1].

Western Blot Analysis[1]

Cell Line:MDA-MB-468 cells
Concentration:10, 20 and 50 μM
Incubation Time:24 h
Result:Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.
体内研究
(In Vivo)

STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice[1].
The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration[1].

Animal Model:Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model[1]
Dosage:160 mg/kg
Administration:Oral gavage, daily for 4 days
Result:Suppressed the growth of SCC-3 cells significantly on the fourth day.
分子量

382.37

性状

Solid

Formula

C22H14N4O3

CAS 号

851095-32-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)